Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Lyon
Clinical trial register · France

Clinical Trials in Lyon, 2026

Every study on the ClinicalTrials.gov registry that lists a site in France and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 9698 matching records held by the registry are in this view. Synced 23 Oct 2026, 03:20 UTC
9698
Studies in scope
all four open statuses
6023
Recruiting now
open to new participants
1034
Lead sponsors
across recruiting studies
Top sites
Paris 38 Lyon 27 Montpellier 21 Marseille 19 Lille 19
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Hospices Civils de Lyon187 AstraZeneca60 Centre Leon Berard51 GCS Ramsay Santé pour l'Enseignement et la Recherche36 Hoffmann-La Roche33 Clear sponsor filter
Site location
Paris38 Lyon27 Montpellier21 Marseille19 Lille19
All 66 locations
Target enrolment
to

Trials with a site in Lyon

27 of 9698 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in France
Start
Recruiting
Eli Lilly and Company
Phase 2
606
Brest, Cholet, Créteil, La Tronche, Lyon, Marseille, Montpellier, Paris
2026-08-07
Recruiting
Eli Lilly and Company
Phase 3
800
Avignon, Besançon, Brest, Clermont-Ferrand, Dijon, Le Mans, Lyon, Montpellier
2025-12-22
Recruiting
Eli Lilly and Company
Phase 3
7,140
Bois-Guillaume, Clermont-Ferrand, La Tronche, Le Coudray, Lyon, Mulhouse, Nantes, Nice
2025-12-01
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Dijon, Epagny Metz-Tessy, La Tronche, Lille, Lyon, Nantes, Nice, Paris
2025-09-02
Recruiting
A Study of LY4175408 in Participants With Advanced Cancer
NCT07046923Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms, Neoplasm Metastasis
DrugsCisplatin·Carboplatin·Pembrolizumab
Eli Lilly and Company
Phase 1
240
Lyon, Villejuif
2025-07-28
Active, closed
Eli Lilly and Company
Phase 3
905
Caen, Corbeil-Essonnes, Le Creusot, Lyon, Marseille, Montpellier, Nantes, Pontoise
2025-04-25
Active, closed
Eli Lilly and Company
Phase 2
45
Bordeaux, Lille, Lyon, Marseille, Paris, Villejuif
2024-10-25
Active, closed
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor
Drugs5Fluorouracil·Leucovorin·Irinotecan·Cetuximab
Eli Lilly and Company
Phase 1
750
Lyon
2024-10-21
Active, closed
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
DrugsLeucovorin·Irinotecan·Cetuximab·Adrucil
Eli Lilly and Company
Phase 1
630
Lyon, Marseille, Toulouse, Villejuif
2024-09-12
Recruiting
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
NCT06400472Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung
DrugsSofe-M·Itraconazole·Bevacizumab·Carboplatin
Eli Lilly and Company
Phase 1
575
Lyon, Saint-Herblain, Toulouse
2024-05-20
Active, closed
Eli Lilly and Company
Phase 3
17,300
Bobigny, Bron, Chambray-lès-Tours, Compiègne, Dijon, Le Coudray, Lille, Lyon
2024-03-05
Active, closed
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
NCT06238479Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
490
Lille, Lyon, Marseille, Strasbourg, Villejuif
2024-03-05
Recruiting
Eli Lilly and Company
Phase 1/2
880
Bordeaux, Lyon, Marseille, Nice, Toulouse, Villejuif
2023-04-17
Recruiting
Eli Lilly and Company
Phase 1
677
Bordeaux, Lyon, Villejuif
2023-01-12
Active, closed
Eli Lilly and Company
Phase 2
46
Bordeaux, Lyon
2022-09-20
Active, closed
Eli Lilly and Company
Phase 1
260
Lyon, Paris, Saint-Herblain, Strasbourg, Villejuif
2022-05-11
Active, closed
Eli Lilly and Company
Phase 3
925
Lyon, Brest, La Chaussée-Saint-Victor, Dijon, Besançon, Montpellier, Nantes, Saint-Herblain
2022-04-14
Active, closed
Eli Lilly and Company
Phase 3
152
Lyon, Marseille, Rouen, Le Plessis-Robinson, Villejuif, Paris
2021-12-20
Active, closed
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
NCT04956640Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms
DrugsOlomorasib·Erbitux·Cetuximab·Pemetrexed
Eli Lilly and Company
Phase 1/2
540
Bordeaux, Lyon, Montpellier, Toulouse, Villejuif
2021-07-19
Active, closed
Eli Lilly and Company
Phase 1
71
Lyon, Paris
2020-06-11
Active, closed
Eli Lilly and Company
Phase 3
261
Lyon, Marseille, Montpellier, La Tronche, Clermont-Ferrand, Paris
2020-02-17
Recruiting
Eli Lilly and Company
Phase 2
105
Bordeaux, Lyon, Paris
2020-01-22
Active, closed
Eli Lilly and Company
Phase 2/3
393
Lyon, Montpellier, Le Mans, La Roche-sur-Yon, Bordeaux, Créteil
2018-11-26
Active, closed
Eli Lilly and Company
Phase 3
5,637
Lyon, Brest, La Chaussée-Saint-Victor, Dijon, Plérin, Besançon, Rennes, Montpellier
2017-07-12
Active, closed
Eli Lilly and Company
Phase 1/2
857
Bordeaux, Lyon, Marseille, Montpellier, Villejuif, Paris
2017-05-02
Active, closed
Eli Lilly and Company
Phase 2
309
Lyon, Bordeaux, Besançon, Lille, Montpellier, Nice, Villejuif
2016-05-19
Active, closed
Eli Lilly and Company
Phase 3
493
Bordeaux, Lyon, Brest, Dijon, Saint-Brieuc, Montpellier, Saint-Herblain, Nancy
2014-11-06
Rows per page Showing 1–27 of 27
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a French investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 October 2026. https://priyalifescience.com/clinical-trials-france/city/lyon

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in France and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,698 studies in total at the last sync on 23 Oct 2026, 03:20 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 27 of those studies with a site in Lyon that also match the filters currently applied.

How many clinical trials are recruiting in Lyon?

9 of the 27 studies on this page are recruiting new participants as of the 23 Oct 2026, 03:20 UTC sync. A further 0 have not yet opened recruitment, 18 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Lyon), 27 studies
PhaseStudiesRecruitingShare
Phase 310337%
Phase 18329.6%
Phase 25218.5%
Phase 1/23111.1%
Phase 2/3103.7%

Most active sponsors

Lead sponsors with the most studies (Lyon)
Lead sponsorStudiesRecruiting
Eli Lilly and Company279
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.